-
公开(公告)号：US08088611B2
公开(公告)日：2012-01-03
申请号：US12784760
申请日：2010-05-21
Applicant: Andrew J. Prongay , Thierry O. Fischmann , Chandra C. Kumar , Vincent S. Madison , Joseph E. Myers , Paul Reichert , Rosalinda Syto , William T. Windsor , Li Xiao , Todd W. Mayhood
Inventor： Andrew J. Prongay , Thierry O. Fischmann , Chandra C. Kumar , Vincent S. Madison , Joseph E. Myers , Paul Reichert , Rosalinda Syto , William T. Windsor , Li Xiao , Todd W. Mayhood
IPC: C12N9/12
CPC classification number: C12N9/1205 , C07K2299/00
Abstract: The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.
Abstract translation: 本发明部分地提供AKT3多肽及其与编码多肽的核酸的使用方法。 例如，本文提供了用于筛选AKT3抑制剂的方法。
-
2.发明授权Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof 失效可溶性，稳定形式的HDM2，其结晶形式及其使用方法公开(公告)号：US07632920B2
公开(公告)日：2009-12-15
申请号：US10822254
申请日：2004-04-09
Applicant: Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
Inventor： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
CPC classification number: C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
Abstract translation: 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
公开(公告)号：US6056957A
公开(公告)日：2000-05-02
申请号：US284516
申请日：1994-08-04
Applicant: Chuan-Chu Chou , Nicholas J. Murgolo , John S. Abrams , Chung-Her Jenh , Mary E. Petro , Jon E. Silver , Stephen Tindall , William T. Windsor , Paul J. Zavodny
Inventor： Chuan-Chu Chou , Nicholas J. Murgolo , John S. Abrams , Chung-Her Jenh , Mary E. Petro , Jon E. Silver , Stephen Tindall , William T. Windsor , Paul J. Zavodny
CPC classification number: C07K16/244 , A61K2039/505 , C07K2317/24
Abstract: A monoclonal antibody is provided which specifically binds to human interleukin-5. Also provided are a hybridoma which produces the monoclonal antibody; complementary DNAs which encode the heavy and light chain variable regions of the monoclonal antibody and CDRs therefrom; humanized monoclonal antibodies; and pharmaceutical compositions comprising the monoclonal antibody or anti-idiotypic antibodies directed against it, humanized monoclonal antibodies, binding fragments, binding compositions or single-chain binding proteins derived from the antibody and a physiologically acceptable carrier.
Abstract translation: 提供特异性结合人白介素-5的单克隆抗体。 还提供了产生单克隆抗体的杂交瘤; 编码单克隆抗体的重链和轻链可变区及其CDR的互补DNA; 人源化单克隆抗体; 以及包含针对其的单克隆抗体或抗独特型抗体的药物组合物，人源化单克隆抗体，结合片段，结合组合物或衍生自抗体的单链结合蛋白和生理上可接受的载体。
-
公开(公告)号：US07446195B2
公开(公告)日：2008-11-04
申请号：US11505263
申请日：2006-08-16
Applicant: Yongqi Deng , Lianyun Zhao , Gerald W. Shipps, Jr. , Patrick J. Curran , M. Arshad Siddiqui , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry
Inventor： Yongqi Deng , Lianyun Zhao , Gerald W. Shipps, Jr. , Patrick J. Curran , M. Arshad Siddiqui , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry
IPC: C07D413/12 , C07D403/12 , C07D409/12 , C07D405/12
CPC classification number: C07D405/12 , C07D333/40 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
Abstract translation: 描述了细胞周期蛋白依赖性激酶2的抑制剂，包括抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。 包括它们的抑制剂和组合物可用于治疗疾病或疾病症状。 本发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法以及治疗疾病或疾病症状的方法。
-
公开(公告)号：US20110158944A1
公开(公告)日：2011-06-30
申请号：US12745031
申请日：2008-11-26
Applicant: Thomas J. Hosted , Jason S. Simon , Marc M. Delorenzo , Donna Marie Carr , William T. Windsor , Ahmed A. Samatar
Inventor： Thomas J. Hosted , Jason S. Simon , Marc M. Delorenzo , Donna Marie Carr , William T. Windsor , Ahmed A. Samatar
CPC classification number: G01N33/57484 , C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , G01N2800/52
Abstract: The present invention provides, inter alia, methods for predicting the sensitivity of a disease, such as cancer, to an ERK1 or ERK2 or MEK inhibitor by detecting the presence of an allele of BRAF in cells mediating the disease. Methods of treatment are also provided.
Abstract translation: 本发明尤其提供了通过检测介导该疾病的细胞中BRAF等位基因的存在来预测ERK1或ERK2或MEK抑制剂等疾病的敏感性的方法。 还提供了治疗方法。
-
Patent Agency Ranking
6.发明申请SOLUBLE, STABLE FORM OF HDM2, CRYSTALLINE FORMS THEREOF AND METHODS OF USE THEREOF 失效可溶性HDM2的稳定形式，其结晶形式及其使用方法公开(公告)号：US20100136620A1
公开(公告)日：2010-06-03
申请号：US12621241
申请日：2009-11-18
Applicant: Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
Inventor： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
CPC classification number: C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
Abstract translation: 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
公开(公告)号：US07511063B2
公开(公告)日：2009-03-31
申请号：US11504869
申请日：2006-08-16
Applicant: Yongqi Deng , Patrick J. Curran , Gerald W. Shipps, Jr. , Lianyun Zhao , M. Arshad Siddiqui , Janeta Popovici-Muller , Jose S. Duca , Alan W. Hruza , Thierry O. Fischmann , Vincent S. Madison , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry
Inventor： Yongqi Deng , Patrick J. Curran , Gerald W. Shipps, Jr. , Lianyun Zhao , M. Arshad Siddiqui , Janeta Popovici-Muller , Jose S. Duca , Alan W. Hruza , Thierry O. Fischmann , Vincent S. Madison , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry
IPC: A61K31/47 , C07D215/14
CPC classification number: C07D409/04 , C07D215/48 , C07D215/50 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/04 , C07D417/06 , C07D417/10
Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
Abstract translation: 描述了基于喹啉的细胞周期蛋白依赖性激酶2抑制剂，包括抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。 包括它们的抑制剂和组合物可用于治疗疾病或疾病症状。 本发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法以及治疗疾病或疾病症状的方法。
-
公开(公告)号：US20080045568A1
公开(公告)日：2008-02-21
申请号：US11504869
申请日：2006-08-16
Applicant: Yongqi Deng , Patrick J. Curran , Gerald W. Shipps , Lianyun Zhao , M. Arshad Siddiqui , Janeta Popovici-Muller , Jose S. Duca , Alan W. Hruza , Thierry O. Fischmann , Vincent S. Madison , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry
Inventor： Yongqi Deng , Patrick J. Curran , Gerald W. Shipps , Lianyun Zhao , M. Arshad Siddiqui , Janeta Popovici-Muller , Jose S. Duca , Alan W. Hruza , Thierry O. Fischmann , Vincent S. Madison , Rumin Zhang , Charles W. McNemar , Todd W. Mayhood , William T. Windsor , Emma M. Lees , David A. Parry
IPC: A61K31/4709 , A61K31/4706 , C07D215/38
CPC classification number: C07D409/04 , C07D215/48 , C07D215/50 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D409/12 , C07D409/14 , C07D413/10 , C07D413/12 , C07D417/04 , C07D417/06 , C07D417/10
Abstract: Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
Abstract translation: 描述了基于喹啉的细胞周期蛋白依赖性激酶2抑制剂，包括抑制剂的组合物，以及使用抑制剂和抑制剂组合物的方法。 包括它们的抑制剂和组合物可用于治疗疾病或疾病症状。 本发明还提供了制备CDK-2抑制剂化合物的方法，抑制CDK-2的方法以及治疗疾病或疾病症状的方法。
-
公开(公告)号：US06645966B2
公开(公告)日：2003-11-11
申请号：US10053335
申请日：2002-01-18
Applicant: William T. Windsor , Patricia C. Weber , Corey O. Strickland , Michael Gelb
Inventor： William T. Windsor , Patricia C. Weber , Corey O. Strickland , Michael Gelb
IPC: A61K31495
CPC classification number: C07D231/12 , A61K31/4178 , A61K31/454 , A61K31/4545 , A61K31/4725 , A61K31/496 , A61K45/06 , C07D233/56 , C07D249/08 , C07D401/14 , C07D403/12 , Y02A50/411 , Y10S514/895 , A61K2300/00
Abstract: Disclosed is a method of treating Malaria comprising administering an effective amount of an FPT inhibitor to a patient in need of such treatment alone or in combination with an additional antimalarial agent and/or agent for reversing antimalarial resistance. Also disclosed are novel Farnesyl Protein Transferase inhibitors.
Abstract translation: 公开了一种治疗疟疾的方法，其包括向需要这种治疗的患者单独施用有效量的FPT抑制剂或与用于逆转抗疟药抗性的另外的抗疟药剂和/或试剂组合施用有效量的FPT抑制剂。还公开了新的法呢基蛋白转移酶抑制剂 。
-
10.发明授权Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides 失效编码可溶性，稳定形式的人类双分子2多肽的多核苷酸公开(公告)号：US08034907B2
公开(公告)日：2011-10-11
申请号：US12621241
申请日：2009-11-18
Applicant: Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
Inventor： Shahriar Shane Taremi , Gaolian Xie , Thomas Hesson , Jose S. Duca , Corey Strickland , William T. Windsor , Vincent S. Madison , Rumin Zhang , Paul Reichert , Yaolin Wang
CPC classification number: C07H21/04 , C07D209/20 , C07K14/47 , C07K2299/00
Abstract: The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes.
Abstract translation: 本发明公开了可溶性的修饰的Hdm2蛋白。 此外，本发明公开了编码本发明的修饰的Hdm2蛋白质的核酸。 本发明还提供了适用于X射线结晶分析的修饰的Hdm2蛋白晶体。 本发明还公开了使用修饰的Hdm2蛋白及其晶体鉴定，选择和/或设计可用作抗癌剂的化合物的方法。 本发明还公开了与蛋白质 - 配体复合物中的修饰的Hdm2蛋白结合的化合物。
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.038 seconds)
